Incorporation of the HIV-1 Microbicide Cyanovirin-N in a Food Product

AbstractAn urgent need exists for HIV-1 microbicides. Here, we describe the in vivo testing of lactic acid bacteria bioengineered to secrete cyanovirin-N. We fed pigtail macaques a yogurt formulation that used bioengineered strains as a starter culture. Cyanovirin-N expression could be detected in the rectal vault during and immediately after feeding. Ex vivo viral challenge of rectal tissue biopsies revealed that peak viral burden was significantly lower in tissue obtained from experimental animals compared with control animals. Formulation of candidate compounds in lactic acid bacteria and their oral administration seems to be a feasible strategy for mucosal delivery of microbicides.

[1]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[2]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[3]  John P. Moore,et al.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. , 2010, The Journal of infectious diseases.

[4]  Qiang Xu,et al.  Engineering of Lactobacillus jensenii To Secrete RANTES and a CCR5 Antagonist Analogue as Live HIV-1 Blockers , 2010, Antimicrobial Agents and Chemotherapy.

[5]  M. Wainberg,et al.  Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice , 2010, PloS one.

[6]  R. Shattock,et al.  Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. , 2009, The Journal of general virology.

[7]  J. Wells,et al.  An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli , 2006, AIDS.

[8]  M. Boyd,et al.  Bioengineering Lactic Acid Bacteria to Secrete the HIV-1 Virucide Cyanovirin , 2005, Journal of acquired immune deficiency syndromes.

[9]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor , 2005, Nature Medicine.

[10]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.

[11]  K. Gustafson,et al.  Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. , 2004, AIDS research and human retroviruses.

[12]  D. Ho,et al.  Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Gustafson,et al.  Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. , 2003, AIDS research and human retroviruses.

[14]  Jean Paul Remon,et al.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.

[15]  D. Teitelbaum,et al.  MUC-2 mucin production in Hirschsprung's disease: possible association with enterocolitis development. , 2003, Journal of pediatric surgery.

[16]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[17]  M. Boyd,et al.  Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells , 2001, Antimicrobial Agents and Chemotherapy.

[18]  J. Alonso,et al.  Generation of Food-Grade Recombinant Lactic Acid Bacterium Strains by Site-Specific Recombination , 2000, Applied and Environmental Microbiology.

[19]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.